{
    "nct_id": "NCT05283330",
    "official_title": "A Phase 1 Open-Label Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors",
    "inclusion_criteria": "* Male or female ≥18 years old with the following histologically confirmed metastatic or recurrent GRPR-expressing tumors:\n\n  1. Metastatic castrate resistant prostate cancer (mCRPC);\n  2. HR+/HER2- breast cancer;\n  3. Colorectal cancer;\n  4. Cervical cancer;\n  5. Cutaneous melanoma;\n  6. Non-small-cell lung cancer (NSCLC).\n* Biopsies must demonstrate the following on immunohistochemistry (IHC):\n\n  * 51-80% positively staining cells; and\n  * Moderate intensity of staining.\n* Subjects with recurrent disease must have progressed on at least 2 prior systemic therapies.\n* Presence of at least 1 site of measurable disease per RECIST 1.1 within 1 month prior to Cycle 1 Day 1. For subjects with prostate cancer, bone lesions may be used to fulfill the eligibility requirements per PCWG3 in lieu of measurable disease per RECIST 1.1.\n* Eastern Cooperative Oncology Group (ECOG) status 0-2.\n* Sufficient bone marrow capacity and organ function as defined by:\n\n  1. White blood cell (WBC) ≥2,500/ mm³\n  2. Absolute neutrophil count (ANC) ≥1500/mm³\n  3. Platelets ≥75,000/mm³\n  4. Hemoglobin (HgB) ≥9.0 g/dL;\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Previous whole-body radiotherapy or peptide receptor radionuclide therapy (PRRT) with either alpha or beta emitters, or subjects with mCRPC who have received radium-223 (²²³Ra).\n* Known hypersensitivity to any component of ²¹²Pb-DOTAM-GRPR1.\n* Exposure to any other GRPR-targeting therapeutic agents.\n* History of chronic pancreatitis\n* History of pneumonitis.\n* Impaired cardiac function defined as:\n\n  1. New York Heart Association (NYHA) class III or IV;\n  2. QTc > 470 msec for females and QTc >450 msec for males on screening electrocardiogram (ECG) or congenital long QT syndrome;\n  3. Acute myocardial infarction or unstable angina pectoris < 3 months prior to study enrollment.\n* Cyclical chemotherapy, radiotherapy, or biologic therapy (e.g. antibodies), continuous or intermittent, small molecule therapeutics, or any investigational agents within a period which is ≤ 5 half-lives or ≤ 4 weeks (whichever is longer) prior to Day 1.",
    "miscellaneous_criteria": ""
}